This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|August 11, 2021
Packaging Components for Parenteral Drug Development
Author(s)BioPharm International Editors
Datwyler offers the StarterPack packaging system designed to aid in the development of parenteral drug packaging.
Advertisement
Packaging component supplier Datwyler has announced the StarterPack packaging system designed to support parenteral drug development by providing components that offer sealing compatibility to prevent leaks or other seal integrity concerns throughout the manufacturing and handling process.
Developed in collaboration with specialty glass maker Schott, the StarterPack has Datwyler’s OmniFlex stoppers and Prime Caps, along with Schott’s adaptiQ vials.
The OmniFlex stopper is sprayed with a proprietary fluoropolymer designed to provide a barrier between drug and rubber to minimize extractables and leachables.
The Prime Caps, designed for high-speed filling lines, come in two sizes. A center-gated disc is designed to promote enhanced machinability, low bioburden and particulate levels, and container closure integrity.
The StarterPack was introduced to North American market on Aug. 11, 2021, at CPHI North America.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5